Rapid Antigen Testing
Cross-source consensus on Rapid Antigen Testing from 1 sources and 7 claims.
1 sources · 7 claims
Uses
How it works
Benefits
Risks & contraindications
Comparisons
Highlighted claims
- Rapid antigen tests should be classified and evaluated as public health surveillance tools, not as diagnostic tests. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- Rapid antigen tests do not register a positive signal until viral load reaches approximately 100,000 particles per milliliter, roughly 100-fold higher than PCR's detection threshold. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- Antigen tests are better than PCR at distinguishing currently infectious individuals from post-infectious individuals. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- Lateral flow paper strip tests are uniquely scalable — even small startups with manufacturing partnerships can produce millions of strips per week. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- True lateral flow paper strip tests can potentially cost under $1 per test and require no equipment, instrument, or connectivity. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- The bottleneck to mass antigen test production is regulatory authorization, not manufacturing capacity. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool
- Antigen tests lose approximately one day of detection at the very start of infection compared to PCR, during which a person is unlikely to be efficiently transmitting. — Rapid Antigen Testing as a COVID-19 Public Health Surveillance Tool